China deal worth $1M to RPCI
Roswell Park Cancer Institute signed a $1 million licensing deal with a Chinese pharmaceutical company.
The agreement for Roswell’s tumor imaging technology was signed with Zhejiang Hisun Pharmaceutical Co. Ltd., one of China’s largest producers of oncology drugs.
The technology, developed by Roswell researcher Ravindra Pandey, shows potential as an anticancer treatment agent and may help improve treatment options for people with cancer. Pandey is director of pharmaceutical chemistry in Roswell’s Photodynamic Therapy Center, and is also a research professor in the University at Buffalo’s Institute of Lasers, Photonics and Biophotonics.
Pandey worked with Roswell’s technology transfer office, which works with researchers and clinicians to identify discoveries that have commercial potential and to market that potential to prospective business partners guaranteed personal loan approval.
Roswell’s President and CEO Donald Trump said the new licensing agreement is a good example of Roswell’s commitment to bringing therapies to market. In a prepared release, Zhejiang Hisun President and CEO Hua Bai said a drug developed with the technology would be “extremely valuable” for patients in China and would greatly enrich the company’s growing oncology drug pipeline.
The announcement follows licensing deals inked this fall with pharmaceutical companies in India and China for Roswell’s photodynamic therapy (PDT) technology using intense doses of red light to treat skin, lung and esophageal cancers.
Filed under: technology by John